View Older Stories View More Recent Stories

Feb 12, 2021 04:46PM Form SC 13G/A FLUIDIGM CORP Filed by: ORBIMED ADVISORS LLC
Feb 12, 2021 04:45PM Form SC 13G/A Crinetics Pharmaceutical Filed by: ORBIMED ADVISORS LLC
Feb 12, 2021 04:43PM Form SC 13G/A Applied Therapeutics Filed by: ORBIMED ADVISORS LLC
Feb 12, 2021 04:42PM Form SC 13G/A Aeglea BioTherapeutics, Filed by: ORBIMED ADVISORS LLC
Feb 12, 2021 04:38PM Form SC 13G/A Adverum Biotechnologies, Filed by: ORBIMED ADVISORS LLC
Feb 11, 2021 09:21PM Form 3 Decibel Therapeutics, For: Feb 11 Filed by: ORBIMED ADVISORS LLC
Feb 10, 2021 05:49PM Form 3 Gemini Therapeutics, For: Feb 05 Filed by: ORBIMED ADVISORS LLC
Feb 9, 2021 06:05AM Form SC 13D/A Arcutis Biotherapeutics, Filed by: ORBIMED ADVISORS LLC
Feb 5, 2021 08:30AM Jubilant Therapeutics Appoints Dr. Robert Glassman to its Board of Directors
Jan 29, 2021 06:13AM Form SC 13D/A Prevail Therapeutics Filed by: ORBIMED ADVISORS LLC
Jan 28, 2021 01:48PM Form SC 13D/A Passage BIO, Inc. Filed by: ORBIMED ADVISORS LLC
Jan 26, 2021 05:21PM Form 4 Prevail Therapeutics For: Jan 22 Filed by: ORBIMED ADVISORS LLC
Jan 25, 2021 07:00AM Umoja Biopharma Appoints Dr. Robert Glassman to its Board of Directors
Jan 21, 2021 04:47PM Form SC 13D Gracell Biotechnologies Filed by: ORBIMED ADVISORS LLC
Jan 19, 2021 07:00AM Terns Announces FDA Clearance of Investigational New Drug (IND) Application for First-in-Human Phase 1 Trial of TERN-501, its THR-Beta Agonist in Development for the Treatment of NASH
Jan 14, 2021 06:01AM Form SC 13D/A Prelude Therapeutics Filed by: ORBIMED ADVISORS LLC
Jan 12, 2021 07:00AM Terns Completes Enrollment in Phase 2a Clinical Trial of TERN-101 in NASH Patients
Jan 11, 2021 04:46PM Form 4 CTI BIOPHARMA CORP For: Jan 07 Filed by: ORBIMED ADVISORS LLC
Jan 11, 2021 07:55AM Vivo Capital Appoints New Managing Partners and Partners
Jan 5, 2021 07:29PM Form 3 Verona Pharma plc For: Jan 01 Filed by: ORBIMED ADVISORS LLC
Jan 5, 2021 04:35PM Terns Appoints Three New Independent Directors to its Board
Jan 5, 2021 08:00AM Pharvaris Expands Board of Directors with Appointment of David Meeker, M.D., as Chair and Robert Glassman, M.D., as Director
Jan 5, 2021 07:00AM Terns Closes $87 Million Series C Financing to Advance NASH Portfolio
Dec 30, 2020 04:44PM Form 4 ALPINE IMMUNE SCIENCES, For: Dec 28 Filed by: ORBIMED ADVISORS LLC
Dec 30, 2020 04:27PM Form SC 13D/A ALPINE IMMUNE SCIENCES, Filed by: ORBIMED ADVISORS LLC
Dec 29, 2020 04:15PM ClearPoint Neuro, Inc. Announces Funding of Additional $7.5M of Existing Convertible Note on Improved Terms
Dec 11, 2020 04:48PM Form SC 13D Silverback Therapeutics, Filed by: ORBIMED ADVISORS LLC
Dec 11, 2020 04:40PM Form SC 13D Kinnate Biopharma Inc. Filed by: ORBIMED ADVISORS LLC
Dec 8, 2020 08:42PM Form 4 Silverback Therapeutics, For: Dec 08 Filed by: ORBIMED ADVISORS LLC
Dec 8, 2020 04:39PM Syros Closes $90.5 Million Strategic Financing
Dec 7, 2020 07:30AM Sinovac Reports Unaudited Third Quarter 2020 Financial Results
Dec 7, 2020 07:17AM Thiel-backed therapy developer AbCellera looks to raise up to $391 million in IPO
Dec 2, 2020 09:08PM Form 3 Kinnate Biopharma Inc. For: Dec 02 Filed by: ORBIMED ADVISORS LLC
Nov 23, 2020 01:00AM Genenta to Appoint Stephen Squinto, Experienced Biotech Executive and Investor, as Chairman
Nov 20, 2020 04:32PM Form SC 13D/A Keros Therapeutics, Inc. Filed by: ORBIMED ADVISORS LLC
Nov 19, 2020 07:00AM Ikena Oncology Assembles Multi-Disciplinary Scientific Advisory Board
Nov 18, 2020 02:43PM Form SC 13D/A Oric Pharmaceuticals, Filed by: ORBIMED ADVISORS LLC
Nov 16, 2020 04:13PM Form 13F-HR ORBIMED ADVISORS LLC For: Sep 30
Nov 13, 2020 08:00AM PMV Pharmaceuticals Reports Third Quarter 2020 Financial Results and Corporate Highlights
Nov 13, 2020 08:00AM PMV Pharmaceuticals Reports Third Quarter 2020 Financial Results and Corporate Highlights
Nov 12, 2020 05:15PM Form SC 13D/A Aerpio Pharmaceuticals, Filed by: ORBIMED ADVISORS LLC
Nov 11, 2020 09:00AM Edgewise Therapeutics Initiates Phase 1 Clinical Trial of EDG-5506 in Becker Muscular Dystrophy
Nov 9, 2020 08:02AM Ikena Oncology to Present New Preclinical Data on AHR Antagonist IK-175 at the Society for Immunotherapy of Cancer’s 2020 Annual Meeting
Nov 6, 2020 05:13PM Form SC 13D Galecto, Inc. Filed by: ORBIMED ADVISORS LLC
Nov 5, 2020 04:05PM Natera Reports Third Quarter 2020 Financial Results
Nov 4, 2020 08:01PM Form 4 Galecto, Inc. For: Nov 02 Filed by: ORBIMED ADVISORS LLC
Nov 2, 2020 11:07AM Petrichor Closes Oversubscribed Fund I at $410 Million
Oct 29, 2020 09:00AM Edgewise Therapeutics Appoints John Moore as General Counsel
Oct 29, 2020 07:00AM Q32 Bio Closes $60 Million Series B Financing, Advances to Clinical Stage Research in Therapeutics Designed to Restore Immune Homeostasis
Oct 28, 2020 09:13PM Form 3 Galecto Inc. For: Oct 28 Filed by: ORBIMED ADVISORS LLC
View More Recent Stories View Older Stories